Genesca, M., McChesney, M.B. & Miller, C.J. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J. Intern. Med. 265, 67-77

Center for Comparative Medicine, California National Primate Research Center, University of California, Davis, CA 95616, USA.
Journal of Internal Medicine (Impact Factor: 6.06). 02/2009; 265(1):67-77. DOI: 10.1111/j.1365-2796.2008.02051.x
Source: PubMed


The recently failed clinical efficacy trial of an acquired immunodeficiency syndrome (AIDS) vaccine that elicits antiviral CD8(+) T-cell responses has emphasized the challenge of producing an effective vaccine against human immunodeficiency virus (HIV). In the simian immunodeficiency virus (SIV)/ rhesus monkey model of AIDS, live-attenuated lentivirus 'vaccines' provide the best protection from uncontrolled viral replication and clinical disease after pathogenic SIV challenge. This review summarizes a recent series of studies in which we show that after vaginal SIV challenge of rhesus macaques immunized with an attenuated lentivirus protection from uncontrolled viral replication is primarily mediated by CD8(+) T cells in the vaginal mucosa. Immunization with a chimeric simian/human immunodeficiency virus (SHIV) results in a systemic infection that induces a moderate population of SIV-specific CD8(+) and CD4(+) T cells with cytolytic potential in the vaginal mucosa. Depletion of CD8(+) T cells at the time of SIV challenge completely abrogates the protection mediated by prior infection with attenuated SHIV. Further after vaginal SIV challenge, the only significant expansion of SIV-specific T cells occurs in the vagina in these animals. No significant expansion of T-cell responses was observed in systemic lymphoid tissues. Thus, the presence of SIV-specific CD8(+) T cells in the vagina on the day of vaginal SIV challenge and a modest expansion of local effector T cells is sufficient to stop uncontrolled SIV replication. It seems that T-cell based vaccine strategies that can elicit mucosal effector CD8(+) T-cell populations and avoid inducing systemic T-cell proliferation upon exposure to HIV have the greatest potential for mimicking the success of live-attenuated lentiviral vaccines.

Download full-text


Available from: Christopher James Miller,
  • Source
    • "The discovery that some of these patients have been infected with naturally attenuated HIV-1 variants by mutation in their nef gene (Live-attenuated) [4] [5] [6] [7] has provided a possible strategy for derivation of a vaccine against the pathogenic HIV- 1. In addition, the most provocative, convincing and reproducible results of protective vaccination in non-human primate model for HIV-1 are those obtained with live-attenuated SIV and SHIV [8] [9] [10]. However, these vaccines, derived from pathogenic strains of viruses were causing persistent infections with integration of their provirus into the genome of vaccinees and they were found to retain pathological properties in infants and reversion to pathogenic phenotype in some adult macaques [11] [12] [13] [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing the safety and the efficacy of existing HIV vaccines is one of the strategies that could help to promote the development of a vaccine for human use. We developed a HIV DNA vaccine (Δ4-SHIVKU2) that has been shown to induce potent polyfunctional HIV-specific T cell responses following a single dose immunization of mice and macaques. Δ4-SHIVKU2 also induced protection when immunized macaques were challenged with homologous pathogenic viruses. In the present study, our aim was to examine whether a chimeric HIV DNA vaccine (CAL-Δ4-SHIVKU2) whose genome is driven by the LTR of the goat lentivirus, caprine arthritis encephalitis (CAEV) expresses efficiently the vaccine antigens and induces potent immune responses in animal models for HIV vaccine. Data of radioimmunoprecipitation assays clearly show that this chimeric genome drives efficient expression of all HIV antigens in the construct. In addition, evaluation of the p24 Gag protein in the supernatant of HEK-293-T cells transfected in parallel with Δ4-SHIVKU2 and CAL-Δ4-SHIVKU2 showed no difference suggesting that these two LTRs are inducing equally the expression of the viral genes. Immunization of mice and macaques using our single dose immunization regimen resulted in induction of similar IFN-γ ELISPOT responses in Δ4-SHIVKU2- and CAL-Δ4-SHIVKU2-treated mice. Similar profiles of T cell responses were also detected both in mice and macaques when multiparametric flow cytometry analyses were performed. Since CAEV LTR is not dependent of Tat to drive viral gene expression and is not functional for integration with HIV integrase, this new vector increases the safety and efficacy of our vaccine vectors and vaccination strategy.
    Vaccine 03/2012; 30(19):2956-62. DOI:10.1016/j.vaccine.2012.02.050 · 3.62 Impact Factor
  • Source
    • "These external factors affect the ratio between target cells and effector cells [19] or influence the phenotype and functionality of CD8 + effector cells [17] [20], all contributing to viral control. From animal model studies, we are learning that the generation and maintenance of a CTL response that is located at the mucosal site of viral transmission is beneficial against mucosal challenge with pathogenic SIVmac [12] [21] "
    [Show abstract] [Hide abstract]
    ABSTRACT: A vaccine inducing protective immunity in mucosal tissues and secretions may stop or limit HIV infection. Although cytotoxic T lymphocytes (CTLs) are clearly associated with control of viral replication in HIV and simian immunodeficiency virus (SIV) infections, there are examples of uncontrolled viral replication in the face of strong CD8+ T-cell responses. The number of functions, breadth, avidity, and magnitude of CTL response are likely to be important factors in the effectiveness of anti-HIV T-cell response, but the location and persistence of effector CD8+ T cells are also critical factors. Although the only HIV vaccine clinical trial targeting cellular immunity to prevent HIV infection failed, vaccine strategies using persistent agents against pathogenic mucosal challenge in macaque models are showing unique success. Thus, the key to control the initial focus of viral replication at the portal of entry may rely on the continuous generation of effector CTL responses at mucosal level.
    BioMed Research International 09/2011; 2011(8):103924. DOI:10.1155/2011/103924 · 2.71 Impact Factor
  • Source
    • "We recently completed a series of studies that defined antiviral T-cell responses in the mucosal and systemic tissues of SHIV-immunized rhesus macaques before and after vaginal SIV challenge. The results of these studies demonstrated that SIV Gag-specific CD8+ T cells in the vaginal mucosa at the time of SIV challenge are the key immune effector function mediating protection in this model [10, 28–30], and that CD8+ lymphocyte depletion leaves SHIV-immunized animals completely unprotected from the vaginal SIV challenge [10, 29]. Despite the evidence for the critical role of SIV-specific CD8+ T-cell responses in SHIV-immunized monkeys, expansion of SIV-specific CD8+ T cells is limited to the vaginal mucosa, and there is minimal immune activation after the SIV challenge [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4(+) T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8(+) T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.
    Current HIV/AIDS Reports 02/2010; 7(1):19-27. DOI:10.1007/s11904-009-0035-7 · 3.80 Impact Factor
Show more